Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Sign of the times as Swiss buy euros, not dollars
2/10/2025
ETMarkets Smart Talk : From BFSI to Healthcare : Key long-term themes for investors over the next 3-5 years from Unmesh (...)
2/10/2025
Bond markets get a boost as RBI holds rates and hints at future easing
2/10/2025
No rate change, no EMI shock : RBI’s move to keep housing demand on track
2/10/2025
12 equity funds outperform with over 30% returns since last Dussehra
2/10/2025
3 largecap mutual funds beat category average and benchmark in one year
2/10/2025
